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AbstrAct
Introduction Noroviruses are the leading cause of 
acute gastroenteritis in all age groups, but illness is 
more severe and causes excess mortality in the elderly, 
particularly those in long-term care. The total burden of 
norovirus disease in the elderly in the UK is poorly defined; 
no current surveillance programmes systematically or 
accurately quantify norovirus infection in those living 
in care homes. The aim of this study is to evaluate an 
enhanced surveillance system for acute gastroenteritis 
among the elderly in care homes.
Methods and analysis We will conduct this prospective 
cohort study in care homes in North West England; 
residents and staff at study care homes will be asked 
to participate. We will prospectively enrol a cohort of 
participants in an enhanced surveillance system to capture 
the incidence of acute gastroenteritis and use multiplex 
PCR to detect pathogens. We will sample symptomatic 
and non-symptomatic participants to understand 
characteristics of norovirus disease and susceptibility to 
infection. We will generate novel data on transmission 
dynamics by collecting data on the pattern of interactions 
within care homes using electronic proximity sensors. 
Comparisons of outbreak and non-outbreak periods will 
be used to quantify the impact of norovirus outbreaks on 
care homes.
Ethics and dissemination The study has been approved 
by the North West–Greater Manchester South NHS 
Research Ethics Committee (REC Reference: 16/NW/0541). 
Study outputs will be disseminated through scientific 
conferences and peer-reviewed publications. This study 
will provide detailed insight on the burden and aetiology 
of acute gastroenteritis in care homes, in addition to 
generating novel data on transmission dynamics and 
risks. The study will identify areas for improving infection 
control practice and allow more accurate modelling of the 
introduction of interventions such as vaccination.
IntroductIon
Noroviruses are endemic in the human popu-
lation and are recognised as the leading 
cause of infectious intestinal disease across 
all ages.1–3 In healthy populations, norovirus 
gastroenteritis is generally mild and self-lim-
iting, but there is increasing evidence that 
it may lead to long-term sequelae4 5 and 
contribute to excess mortality in the elderly 
and the immunocompromised.6–13 The 
elderly, particularly those in long-term care, 
suffer a longer duration of illness with more 
severe symptoms, contributing to excess 
mortality.6 7 
The factors that facilitate sustained trans-
mission in health and social care settings 
are likely to be the result of a combination 
of the environment, behaviour patterns asso-
ciated with patients, visitors and staff, the 
characteristics of the norovirus strains and/
or host-related factors that influence suscep-
tibility to disease.14 15 At present, the main 
approaches to preventing and controlling 
norovirus outbreaks, common across several 
national guidelines, include promotion of 
hand hygiene, patient isolation (separation 
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Protocol
strengths and limitations of this study
 ► This prospective cohort study will provide detailed 
information on the incidence, risk factors for and 
aetiology of acute gastroenteritis in care homes.
 ► This study will use novel methods to generate data 
on the structure of interactions between persons in 
care homes.
 ► The results of this study will provide clinicians and 
policy-makers with information to improve infection 
control and prevention in care homes.
 ► The results of this study will inform modelling to 
estimate the burden of acute gastroenteritis in 
care homes in the UK and the potential impact of a 
norovirus vaccine targeted at this population.
 ► It may be that participants at study sites 
systematically differ from others at care homes both 
in the UK and in other countries in aspects such as 
the demography, socioeconomic status and level of 
morbidity of participants.
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Table 1 Summary of study components
Study 
component Study component description
A Enhanced surveillance system
B Pathogen testing
C Individual norovirus risk factor study
D Microbiota as a risk factor for norovirus 
infection and/or disease
E Transmission dynamics study
F Norovirus outbreak risk factors
G Quantitative assessment of the impact of 
norovirus outbreaks
of symptomatic patients) and cohorting (grouping of 
patients based on symptoms), staff exclusion from work, 
visitor restrictions, enhanced environmental cleaning 
and disinfection, and closures of units.16–20
The total burden of norovirus disease in the elderly 
population in the UK is poorly defined, despite the 
widespread acknowledgement that the elderly and, in 
particular, those in long-term care are worst affected 
by norovirus illness. There are currently no surveil-
lance programmes that can systematically or accurately 
quantify the levels of any cause of norovirus-specific 
gastroenteritis among the growing ageing population 
living in care homes. The ageing population in the UK 
means that those over 65 years old are the fastest growing 
sector of the population, which will result in increasing 
pressure and demand for healthcare and long-term resi-
dential care in the future.21 Norovirus infections are 
known to be more severe in this sector of the population, 
contributing to excess hospitalisation and mortality.6 22–25
The relative importance of different drivers of transmis-
sion and factors that impact on susceptibility to disease 
and more severe illness among this population are poorly 
understood. Norovirus infections of the elderly are asso-
ciated with prolonged shedding and longer duration of 
symptoms,26 27 and it has been proposed that the elderly 
may contribute to the emergence of new epidemic strains 
that spread across the population.28
AIMs And objEctIvEs
The aim of this study is to evaluate an enhanced surveil-
lance system for acute gastroenteritis among the elderly 
in care homes. This will provide data that can then 
be extrapolated and used in mathematical models to 
calculate the burden of norovirus infections in the elderly 
in long-term residential care in the UK and the potential 
impact of a norovirus vaccine specifically targeted to this 
population.
study objectives
1. To study the feasibility of using an enhanced acute 
gastroenteritis surveillance system in care homes to 
generate novel descriptive data regarding norovirus 
infection in this population;
2. To quantitatively assess the impact of norovirus illness 
on residential care institutions;
3. To generate novel data on transmission dynamics 
and risks, by collecting both data on the pattern of 
interactions within care homes and data on virus char-
acterisation;
4. To understand characteristics of norovirus disease 
and susceptibility to infection (viral load, shedding 
duration, norovirus-specific IgA antibodies, blood 
group and microbiota composition (Diversity Index)) 
and use this to inform transmission dynamics studies, 
by sampling symptomatic and non-symptomatic par-
ticipants;
5. To understand the risk factors associated with 
acquiring norovirus infection in residential care 
settings during a norovirus outbreak.
MEthods And AnAlysIs
study setting and location
The study will take place in care homes in North West 
England. Care homes are defined as places offering 
accommodation and personal care for people who may 
not be able to live independently. This includes nursing 
homes that offer the same type of care but with the addi-
tion of 24-hour medical care from a qualified nurse.
The North West of England has a population of over 
7 million people. Within the region, there is a mixture 
of affluent and deprived areas, urban and rural. The 
study sites will be in the metropolitan boroughs of 
Liverpool and Sefton. The combined population of these 
two boroughs is 746 604, of which 130 458 (17.47%) 
are aged 65 or older.29 Within the two boroughs, there 
are 133 care homes registered with the Care Quality 
Commission.30
sampling frame and strategy
The sampling frame is the total number of residential 
care homes for the elderly in the metropolitan boroughs 
of Liverpool and Sefton, registered with the Care Quality 
Commission. The sampling strategy is a convenience 
sample of sites that are approached and agree to partici-
pate. We will aim to recruit four study sites prospectively.
study overview and study design
The study will be based on a prospective cohort of partic-
ipants in the enhanced surveillance system (component 
A). The other six study components are outlined in 
table 1 and include different epidemiological, microbio-
logical and quantitative elements.
study site inclusion process
Potential study sites will be recruited in two ways. Study 
sites will be recruited prospectively to be included in all 
study components. These sites will be approached through 
the Liverpool Community Health Trust (LCHT). We will 
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approach care homes after discussion with LCHT so that 
those approached are representative of the care homes 
in the sampling frame (eg, in size and complexity). Study 
sites will also be recruited reactively. Potential study sites 
within the sampling frame will report to the Public Health 
England (PHE) Health Protection Team that they are 
experiencing an outbreak of gastroenteritis (as required 
by The Health and Social Care Act 2008). If this reported 
outbreak meets the study definition, PHE will inform the 
study team who will contact the study site to ask them to 
participate. Two members of the study team are substan-
tive employees of PHE; their job roles entail surveillance 
of infectious disease outbreaks, and they will, therefore, 
be informed of relevant outbreaks. Potential study sites 
that are reactively recruited will be asked to participate 
in the study components B, D, F and G. Studies recruited 
both prospectively and reactively will have background 
information collected on the type of residents, structure, 
capacity and staffing at the care home.
study sample size
Data from PHE surveillance of gastrointestinal illness in 
care homes in Cheshire and Merseyside indicate that the 
median number of residents is 32 and the median number 
of staff is 35. On the basis of these estimates, it would be 
expected that there are an average of 67 participants per 
study site. The study will aim to recruit four study sites 
prospectively. It is therefore expected that approximately 
268 participants will be included in all components of the 
study.
Enhanced surveillance system (component A)
The study population will be residents and staff at study 
sites who have provided informed consent. Cases are 
defined as persons in the study population with the 
following:
 ►  Vomiting—two or more episodes of vomiting in a 
24-hour period OR 
 ► Diarrhoea—three or more loose stools in a 24-hour 
period OR 
 ► Vomiting AND diarrhoea—one or more episodes of 
BOTH symptoms in a 24-hour period
Confirmed cases will be defined as:
 ►  Cases with a positive laboratory diagnosis of an infec-
tious cause
Causes of diarrhoea and vomiting should be believed 
to be infectious. Non-infectious causes, which are not to 
be counted, would include long-standing diarrhoea asso-
ciated with disability or incontinence, and ingestion of 
laxative drugs.
Current numbers of residents and staffing levels at each 
care home will be collected using a questionnaire, filled 
in by a member of staff in conjunction with a research 
nurse on the first Monday of each month. Faecal samples 
will be obtained for each case to determine whether the 
illness is caused by norovirus or another gastrointes-
tinal pathogen; this sample will be collected as soon as 
possible after onset of illness. For each case, information 
including onset date, medical history, duration of symp-
toms, complications, hospitalisation and outcome (eg, 
death) will be collected using a questionnaire. This ques-
tionnaire will be filled in by a member of staff on the same 
day as the faecal sample is collected, then checked and 
collected by a research nurse on the first Monday of each 
month.
We will describe the characteristics of the surveil-
lance system and the epidemiology of cases it captures. 
Non-cases will contribute to the person-time at risk. We 
will calculate incidence rates for person-time at risk in 
each study site and for the study in total. We will compare 
the burden of norovirus, viral gastroenteritis of another 
cause and gastroenteritis of an unknown cause. We will 
describe the duration and severity of illness.
Pathogen testing (component b)
Stool samples will be collected for cases as described for 
the enhanced surveillance system. The specimen request 
form will be completed and the sample and request 
form will be submitted to a laboratory to be tested for 
gastrointestinal pathogens. Samples will be posted using 
approved containers for the transport of diagnostic spec-
imens. Samples will be sent to Liverpool Clinical Labora-
tories, based in the Royal Liverpool University Hospital.
Diagnostic tests will be done in real time and results 
reported to the study team. Samples will be tested for 
15 pathogens using Luminex xTAG Gastrointestinal 
Pathogen Panel. Positive results will be reported to the 
study team and copied to the patient’s general practi-
tioner. The operation of this study will not interfere with 
public health actions. A portion of each virus positive 
sample will be sent for genotyping and further character-
isation. This work will not be conducted in real time and 
will not lead to public health action.
We will describe the proportion positive for norovirus 
and for other infectious causes of acute gastroenteritis. 
We will describe the sequencing results of norovirus-posi-
tive samples over time, by study site and in relation to the 
results of the enhanced surveillance system.
Individual norovirus risk factor study (component c)
For each case with a norovirus positive laboratory result, 
where feasible, sequential stool samples will be taken at 
three time points (from onset): days 0–3, days 6–8 and 
days 12–15. For each sample, viral load will be measured 
by qRT-PCR.
For the purpose of testing for blood group, all partici-
pants enrolled prospectively in the enhanced surveillance 
system will be asked to provide a sample of saliva. Samples 
will be taken by research nurses within a month of consent 
being obtained. Laboratory analysis will use one enzyme 
immunoassay (EIA) for the detection of blood group 
antigens in saliva and another EIA for the detection of 
norovirus-specific IgA and IgG in saliva. Results will be 
standardised measuring total IgA.
We will compare proportion and level of cases with viral 
shedding over time. We will categorise study participants 
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by blood group category and compare case incidence 
rates (based on person-time at risk) by pathogen.
Microbiota as a risk factor for norovirus infection and/or 
disease (component d)
All participants enrolled prospectively in the enhanced 
surveillance system will be asked to provide a stool sample 
at the beginning of the study. Samples will be taken 
by research nurses within a month of consent being 
obtained. If study participants test positive for norovirus 
and provide a sequential stool sample, as detailed in study 
component C, this sample will also be used for microbiota 
investigations, in addition to the baseline sample.
Stool samples arriving for microbiota analysis will have 
norovirus viral load measured by qRT-PCR. Samples for 
microbiota analysis will be stored frozen for a maximum of 
2 weeks prior to DNA extraction. Samples will be treated 
by bead beating and lysozyme prior to DNA extraction 
using a commercially available extraction kit. We will 
store two aliquots of each stool samples at −80°C, adding 
nucleic acid stabilising buffer to one of them. Stool DNA 
extraction will be conducted from the aliquots in stabi-
lising buffer, in batches, once or twice a month.
DNA samples will undergo metataxonomic analysis 
with 16S rDNA in the first instance. An aliquot of DNA 
will be stored for further metagenomic analysis, subject 
to obtaining additional funding. The 16S rDNA PCR 
strategy will use a nested dual index protocol to amplify 
and barcode the variable V3–V4 region (319 f—5′ 
ACTCCTACGGGAGGCAGCAG 3′ and 806 r—5′  GGAC-
TACHVGGGTWTCTAAT 3′) resulting in ~469 bp PCR 
product.31 Then barcoded 16S PCR products will be 
multiplexed and run in batches of up to 96 on the MiSeq 
to produce 2×300 bp reads.
Sequences generated on MiSeq will undergo a vali-
dated error correction protocol. We will trim the start and 
end of the reads based on quality scores using a tool such 
as Sickle (https:// github. com/ najoshi/ sickle), error 
correction with BayesHammer32 followed by overlap-
ping reads with PANDAseq33 with a minimum overlap of 
10 bp for V3/V4 reads. These corrected and overlapped 
reads will then be analysed with QIIME.34 USEARCH 
will be run using de novo and open reference opera-
tional taxonomic unit (OTU) clustering methods, and de 
novo chimara detection conducted with software such as 
UCHIME. Taxonomy will be assigned to OTUs using the 
naive Bayesian RDP Classifier using both the SILVA and 
GREENGENES taxonomic databases.
Estimates of within-sample species richness (number of 
OTUs) and diversity (Shannon Index) at multiple rarefac-
tion depths will be compared between cases and controls, 
and between samples obtained from cases during the 
acute and convalescent phases, using Student’s t-test.
Weighted and unweighted Unifrac will be used to 
measure distances in microbiota composition between 
these groups. These results will be visualised using 
principal coordinates analyses and statistically signif-
icant clusters identified using adonis. Random Forest 
regression will be used to identify OTUs that distinguish 
norovirus cases and diarrhoeal or asymptomatic controls 
and between samples obtained from cases during the 
acute and convalescent phases.
transmission dynamics study (component E)
We will quantify potential transmission paths into and 
within care homes using a survey instrument (an individu-
ally worn electronic proximity sensor) that has previously 
proved successful in characterising interaction patterns 
in a study of influenza in an American school and in other 
settings.35–37
The study population will be participants at care homes 
enrolled in the enhanced surveillance system and visi-
tors to those homes on the days of data collection. Visi-
tors on the days in question will be consented using a 
specific consent form. Four 24-hour study periods will be 
chosen for the transmission dynamics study. The 24-hour 
periods selected will be a convenience sample based on 
study team availability and study site access. Interactions 
between individuals will be quantified using electronic 
proximity sensors, called motes, which are worn by or 
located next to participants and detect and record the 
nearby presence of other motes. The age, gender and 
role of individual in the care home will be collected. A 
member of the study team will be present at the study 
site of the days of data collection to consent visitors and 
distribute the motes.
We will measure continuous, uninterrupted inter-
actions between participants. We will sum the total 
durations of interactions over each 24-hour period and 
create participant contact networks with edge weights 
proportional to the total number of mutual interactions. 
We will use social network analysis and transmission 
models to relate infection attack rates and dynamics to 
measured interaction patterns.
norovirus outbreak risk factors (component F)
One of the objectives of this study is to understand the 
risk factors associated with acquiring norovirus infection 
in care homes during a norovirus outbreak. An outbreak 
will be defined as two or more cases (as defined in compo-
nent A) occurring in an institution, with onset of illness 
within 5 days. An outbreak will be considered finished if 
no new cases are ascertained for 7 days. An outbreak-free 
period will be defined as a period of time ending 3 weeks 
before an outbreak is declared and beginning 3 weeks 
after an outbreak is considered over in an institution.
Participants enrolled at a study site where an outbreak 
has occurred will form a cohort in which we will investi-
gate risk factors associated with infection. A member of 
the study team will administer a questionnaire to partic-
ipants; the questionnaire covers demographic, illness 
and medication information, along with food and drink 
history and information on time spent in different areas 
of the study site.
We will compare patient characteristics and exposure 
histories between cases and non-cases, with the null 
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hypothesis that risk factors have a similar distribution in 
cases and non-cases. We will investigate differences using 
univariable and multivariable analyses.
Quantitative assessment of the impact of norovirus outbreaks 
(component G)
A case-crossover approach will be used to compare 
resource usage and operational efficiency in residential 
institutions during outbreak periods and outbreak-free 
periods (as defined in component F). Data collected will 
include the symptoms of ill staff, the days of work lost, the 
need for additional staff (bank or agency) and additional 
cleaning. Operational impact data collected will include 
isolation of residents, transfers to healthcare facilities and 
blocking/delays on places to new residents. These data 
will be collected by a member of the study team from a 
member of the affected care home.
Data will be collected for the whole period when an 
outbreak is occurring. The increased resource usage 
during outbreaks will be measured by comparing periods 
when outbreaks are occurring with periods when there 
is not an outbreak occurring. Measurement in outbreak-
free periods will take place 3 weeks after the end of 
outbreaks so that activity will resettle to normal levels. We 
will test the null hypothesis that norovirus outbreaks do 
not have an impact on the resource usage of care homes.
EthIcs And dIssEMInAtIon
consent
Informed consent will be obtained for each participant 
with capacity to consent. For those persons without 
capacity to consent, a nominated person who meets the 
criteria described in Section 32 of the Mental Capacity 
Act 2005 will be asked to provide consent.
timeline
Administrative and logistical arrangements have been 
made to start the study in February 2017 and collect data 
for a 2-year period.
dissemination of findings
Study results will be presented and discussed at appro-
priate scientific meetings, and published in open access 
peer-reviewed journals. Appropriate metadata will 
be published with the research data to enable other 
researchers to identify whether the data could be suitable 
for their own research.
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